Overview

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Arrowhead Pharmaceuticals
Treatments:
Entecavir
Histamine Antagonists
Histamine H1 Antagonists
Tenofovir